Corcept Therapeutics | CORT - Interest Expense On Debt


Corcept Therapeutics reported $823.61M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alaunos Therapeutics USD 1.07M 215K Jun/2023
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Ardelyx USD 5.76M 37K Dec/2025
Assertio Holdings USD 758K 1000 Jun/2024
Aurora Cannabis CAD 2.11M 116K Dec/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Canopy Growth CAD 7.34M 1.46M Dec/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
J&J USD 18M 290M Sep/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Merck USD 412M 85M Dec/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 304M 23M Dec/2025
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.89M 387K Dec/2025
Pfizer USD 711M 59M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
TG Therapeutics USD 6.53M 187K Dec/2025